BioSpace News Archive

Business

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023.

August 8, 2023
·
33 min read
FDA

Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson’s Disease

Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, enabling the company to proceed with a clinical trial for ANPD001.

August 8, 2023
·
4 min read
Drug Development

Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development

Sparian Biosciences, Inc., a clinical-stage CNS-focused biopharmaceutical company, announced that it has been awarded a $19 million, five-year grant to fund development of SBS-518 from IND submission through Phase 1 clinical development.

August 8, 2023
·
3 min read
Drug Development

AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsTopline data expected as early as Q1 2024

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions (“AMP-518”).

August 8, 2023
·
4 min read
Business

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

Madrigal Pharmaceuticals, Inc. today provides a summary of recent corporate accomplishments and reports second quarter 2023 financial results.

August 8, 2023
·
16 min read
Business

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2023.

August 8, 2023
·
9 min read
Business

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023.

August 8, 2023
·
14 min read
Business

Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023.

August 8, 2023
·
10 min read
BioMidwest

Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection

Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection.

August 8, 2023
·
4 min read
Business

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Processa Pharmaceuticals, Inc. announces today that industry veteran George Ng has been appointed to serve as the Company’s Chief Executive Officer and as a Board Director as of August 8, 2023.

August 8, 2023
·
6 min read